Receiving a notification from Nasdaq about non-compliance with the minimum bid price requirement is a significant regulatory issue that can affect investor confidence and potentially lead to delisting if not rectified. This news is likely to negatively impact investor sentiment and the stock price of NeuBase Therapeutics in the short term.